Amino-terminal-pro-B-type natriuretic peptide levels and low diastolic blood pressure: Potential relevance to the diastolic J-curve

Journal of Hypertension

Volumn 32, Issue 11, 2014, Pages 2158-2165

  Campbell, Duncan J ^a,b   McGrady, Michele ^b   Prior, David L ^a,b,d   Coller, Jennifer M ^d   Boffa, Umberto ^e   Shiel, Louise ^c   Liew, Danny ^b   Wolfe, Rory ^c   Stewart, Simon ^f   Reid, Christopher M ^c   Krum, Henry ^c  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Amino terminal pro B type natriuretic peptide; Cardiac disease; Cardiovascular risk; DBP; J curve; Pulse pressure; SBP

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; THIAZIDE DIURETIC AGENT; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADJUSTMENT; ADULT; AGE; AGED; ARTICLE; BLOOD LEVEL; CARDIAC IMAGING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIASTOLIC BLOOD PRESSURE; DIASTOLIC J CURVE; ECG ABNORMALITY; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PULSE RATE; STUDY DESIGN; AUSTRALIA; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIASTOLE; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; STATISTICAL MODEL;

AGED; AUSTRALIA; BIOMARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIASTOLE; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBINS; HUMANS; LOGISTIC MODELS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RISK FACTORS;

EID: 84927627391     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000320     Document Type: Article

References (34)

1. Mancia G, Grassi G. Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the arguement. Hypertension 2014; 63:29-36.
2. Verdecchia P, Angeli F, Mazzotta G, Garofoli M, Reboldi G. Aggressive blood pressure lowering is dangerous: the J-curve: con side of the arguement. Hypertension 2014; 63:37-40.
3. Farnett L, Mulrow CD, LinnWD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA 1991; 265:489-495.
4. Boutitie F, Gueyffier F, Pocock S, Fagard R, Boissel JP. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data. Ann Int Med 2002; 136:438-448.
5. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005; 16:2170-2179.
6. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Int Med 2006; 144:884-893.
7. Protogerou AD, Safar ME, Iaria P, Safar H, Le Dudal K, Filipovsky J, et al. Diastolic blood pressure and mortality in the elderly with cardiovascular disease. Hypertension 2007; 50:172-180.
8. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009; 27:1360-1369.
9. Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, LaRosa JC. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J 2010; 31:2897-2908.
10. Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP. What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation 2010; 122:2142-2151.
11. Dorresteijn JA, van der Graaf Y, Spiering W, Grobbee DE, Bots ML, Visseren FL. Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease: J-curve revisited. Hypertension 2012; 59:14-21.
12. Chalmers J. Is a blood pressure target of <130/80mm Hg still appropriate for high-risk patients? Circulation 2011; 124:1700-1702.
13. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL Jr, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115:2761-2788.
14. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
15. Rademaker MT, Richards AM. Cardiac natriuretic peptides for cardiac health. Clin Sci (Lond) 2005; 108:23-36.
16. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007; 49:1733-1739.
17. Campbell DJ. Can measurement of B-type natriuretic peptide levels improve cardiovascular disease prevention? Clin Exp Pharmacol Physiol 2008; 35:442-446.
18. Campbell DJ, Woodward M, Chalmers JP, Colman SA, Jenkins AJ, Kemp BE, et al. Prediction of heart failure by amino-terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease. Hypertension 2005; 45:69-74.
19. Campbell DJ, Woodward M, Chalmers JP, Colman SA, Jenkins AJ, Kemp BE, et al. Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein and renin in subjects with cerebrovascular disease. Circulation 2005; 112:110-116.
20. Campbell DJ, Woodward M, Chalmers JP, Colman SA, Jenkins AJ, Kemp BE, et al. Soluble vascular cell adhesion molecule 1 and Nterminal pro-B-type natriuretic peptide in predicting ischemic stroke in patients with cerebrovascular disease. Arch Neurol 2006; 63:60-65.
21. Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, et al. Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2006; 114:201-208.
22. Heart Protection Study Collaborative Group. N-terminal pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF Heart Protection Study. J Am Coll Cardiol 2007; 49:311-319.
23. Wallén T, Landahl S, Hedner T, Nakao K, Saito Y. Brain natriuretic peptide predicts mortality in the elderly. Heart 1997; 77:264-267.
24. Ueda R, Yokouchi M, Suzuki T, Otomo E, Katagiri T. Prognostic value of high plasma brain natriuretic peptide concentrations in very elderly persons. Am J Med 2003; 114:266-270.
25. McDonagh TA, Cunningham AD, Morrison CE, McMurray JJ, Ford I, Morton JJ, Dargie HJ. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001; 86:21-26.
26. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, et al. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J 2007; 28:1374-1381.
27. McKie PM, Rodeheffer RJ, Cataliotti A, Martin FL, Urban LH, Mahoney DW, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large communitybased cohort free of heart failure. Hypertension 2006; 47:874-880.
28. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350:655-663.
29. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293:1609-1616.
30. Pedersen F, Raymond I, Kistorp C, Sandgaard N, Jacobsen P, Hildebrandt P. N-terminal pro-brain natriuretic peptide in arterial hypertension: a valuable prognostic marker of cardiovascular events. J Card Fail 2005; 11:S70-S75.
31. Linssen GC, Bakker SJ, Voors AA, Gansevoort RT, Hillege HL, de Jong PE, et al. N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J 2010; 31:120-127.
32. Campbell DJ, McGrady M, Prior DL, Coller JM, Boffa U, Shiel L, et al. Most individuals with treated blood pressures above target receive only one or two antihypertensive drug classes. Intern Med J 2013; 43:137-143.
33. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470.
34. Fradley MG, Larson MG, Cheng S, McCabe E, Coglianese E, Shah RV, et al. Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham Heart Study). Am J Cardiol 2011; 108:1341-1345.